Viatris Net Change in Intangible Assets 2010-2025 | VTRS
Viatris annual/quarterly net change in intangible assets history and growth rate from 2010 to 2025. Net change in intangible assets can be defined as the overall change from the sale and purchase of intangible assets including patents, rights and capitalized software.
- Viatris net change in intangible assets for the quarter ending March 31, 2025 was $-0.019B, a 1780% increase year-over-year.
- Viatris net change in intangible assets for the twelve months ending March 31, 2025 was $-0.071B, a 67.02% decline year-over-year.
- Viatris annual net change in intangible assets for 2024 was $-0.021B, a 78.67% decline from 2023.
- Viatris annual net change in intangible assets for 2023 was $-0.098B, a 163.51% increase from 2022.
- Viatris annual net change in intangible assets for 2022 was $-0.037B, a 29.12% decline from 2021.
| Viatris Annual Net Change in Intangible Assets (Millions of US $) |
|
|---|---|
| 2024 | $-21 |
| 2023 | $-98 |
| 2022 | $-37 |
| 2021 | $-52 |
| 2020 | $-438 |
| 2019 | $-193 |
| 2018 | $-944 |
| 2017 | $-620 |
| 2016 | $-360 |
| 2015 | $-507 |
| 2014 | $-420 |
| 2013 | $-61 |
| 2012 | $-80 |
| 2011 | $N/A |
| 2010 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $10.563B | $14.739B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $146.067B | 27.09 |
| CVS Health (CVS) | United States | $78.811B | 9.80 |
| Elevance Health (ELV) | United States | $66.101B | 8.89 |
| Cencora (COR) | United States | $56.558B | 19.68 |
| DiDi Global (DIDIY) | China | $24.238B | 25.75 |
| Labcorp Holdings (LH) | United States | $22.089B | 17.43 |
| Natera (NTRA) | United States | $19.248B | 0.00 |
| BioMerieux (BMXMF) | France | $17.068B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $14.897B | 0.00 |
| ICON (ICLR) | Ireland | $14.657B | 14.10 |
| CochLear (CHEOY) | Australia | $13.278B | 0.00 |
| Solventum (SOLV) | United States | $12.626B | 13.37 |
| Medpace Holdings (MEDP) | United States | $12.299B | 32.55 |
| Revvity (RVTY) | United States | $10.708B | 18.58 |
| Avantor (AVTR) | United States | $9.404B | 13.66 |
| Sonic Healthcare (SKHHY) | Australia | $8.886B | 0.00 |
| Charles River Laboratories (CRL) | United States | $8.654B | 16.96 |
| HealthEquity (HQY) | United States | $8.544B | 37.42 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.505B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $4.851B | 32.64 |
| Amplifon S.p.A (AMFPF) | Italy | $3.871B | 21.19 |
| BrightSpring Health Services (BTSG) | United States | $3.746B | 34.37 |
| Sotera Health (SHC) | United States | $3.382B | 19.22 |
| GeneDx Holdings (WGS) | United States | $2.953B | 68.10 |
| Surgery Partners (SGRY) | United States | $2.867B | 37.28 |
| Concentras Parent (CON) | United States | $2.615B | 15.11 |
| Organon (OGN) | United States | $2.610B | 2.77 |
| Alignment Healthcare (ALHC) | United States | $2.572B | 0.00 |
| Progyny (PGNY) | United States | $2.014B | 44.34 |
| Premier (PINC) | United States | $1.772B | 13.45 |
| GoodRx Holdings (GDRX) | United States | $1.747B | 34.93 |
| PACS (PACS) | United States | $1.710B | 0.00 |
| Ardent Health (ARDT) | United States | $1.528B | 6.51 |
| Teladoc Health (TDOC) | United States | $1.298B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.213B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.065B | 8.10 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.875B | 300.00 |
| Agilon Health (AGL) | United States | $0.791B | 0.00 |
| CareDx (CDNA) | United States | $0.716B | 11.18 |
| AMN Healthcare Services Inc (AMN) | United States | $0.712B | 6.67 |
| Embecta (EMBC) | United States | $0.611B | 4.11 |
| So-Young (SY) | China | $0.501B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.479B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.471B | 0.00 |
| Nutex Health (NUTX) | United States | $0.467B | 7.06 |
| LifeMD (LFMD) | United States | $0.459B | 0.00 |
| Omada Health (OMDA) | $0.455B | 0.00 | |
| SBC Medicals (SBC) | United States | $0.455B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.454B | 10.23 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.369B | 0.00 |
| Enhabit (EHAB) | United States | $0.338B | 27.83 |
| Oncology Institute (TOI) | United States | $0.329B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.270B | 0.00 |
| Beauty Health (SKIN) | United States | $0.202B | 0.00 |
| DocGo (DCGO) | United States | $0.145B | 23.67 |
| Sera Prognostics (SERA) | United States | $0.108B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.096B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.061B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| KindlyMD (NAKA) | United States | $0.058B | 0.00 |
| Biodesix (BDSX) | United States | $0.055B | 0.00 |
| ModivCare (MODV) | United States | $0.044B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.041B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.039B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.017B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.013B | 0.00 | |
| Intelligent Bio Solutions (INBS) | United States | $0.011B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.007B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |